Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting

Ocuphire Pharma announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group, ARVO SIG, panel and the American Society of Retina Specialists, ASRS, 42nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy, DR. APX3330 is an oral small-molecule inhibitor of Ref-1 being developed for the treatment of non-proliferative diabetic retinopathy. DR affects approximately 10 million of the 38 million Americans with diabetes and is the leading cause of blindness in working-age adults. Ocuphire’s Chief Executive Officer, George Magrath, M.D., M.B.A., M.S., will participate in an ARVO SIG panel discussion, “Oral Medications for the Management of Retinal Diseases.” The discussion will focus on the potential of oral medications in treating retinal diseases earlier in the disease process, the need to develop new therapies with differentiated mechanisms of action, and the challenges and opportunities associated with developing these oral medications.